TG Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on TG Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date TG Therapeutics Inc Strategy Report
- Understand TG Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on TG Therapeutics Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
WO2022104150A1 | Application | TRIPLE COMBINATION TO TREAT B-CELL MALIGNANCIES | A61K31/5025; A61K31/5025; A61K31/519; A61K31/519; A61K39/3955; A61K39/39558; A61K45/06; A61K45/06; A61P35/00; A61P35/00; A61P35/02; C07K16/2887; C07K16/2887; C07K2317/24 | May 19, 2022 |
US20220143026A1 | Application | TRIPLE COMBINATION TO TREAT B-CELL MALIGNANCIES | A61K31/5025; A61K31/519; A61K39/3955; A61K45/06; A61P35/00; C07K16/2887 | May 12, 2022 |
CA2890176C | Grant | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | A61K31/519; A61K39/3955; A61K45/06; A61P11/00; A61P11/02; A61P11/06; A61P19/02; A61P29/00; A61P35/00; A61P35/02; A61P37/00; A61P43/00; C07K16/2887; C07K2317/24; C07K2317/73 | December 14, 2021 |
US20210169878A1 | Application | COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS | A61K31/4155; A61K31/416; A61K31/4985; A61K31/506; A61K31/519; A61K39/3955; A61K45/06; A61K9/0019; A61P35/02; C07K16/2887; C07K2317/24; C07K2317/41; C07K2317/732 | June 10, 2021 |
SI3150256T1 | Grant | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | A61K31/519; A61K39/3955; A61K45/06; A61P11/00; A61P11/02; A61P11/06; A61P19/02; A61P29/00; A61P35/00; A61P35/02; A61P37/00; A61P43/00; C07K16/2887; C07K2317/24; C07K2317/73 | March 31, 2021 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer